PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Nova Laboratories Limited
- Target Recruit Count
- 180
- Registration Number
- NCT06923111
- Locations
- 🇬🇧
Basildon University Hospital, Basildon, Essex, United Kingdom
🇬🇧Noah's Ark Children's Hospital for Wales, Cardiff, Leicestershire, United Kingdom
🇬🇧University College London Hospital, London, North London, United Kingdom
Bioequivalence of Azathioprine Suspension 10 mg/mL (Jayempi) Versus Azathioprine Tablet 50mg (Imurek®)
- Conditions
- Therapeutic Equivalency
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Nova Laboratories Limited
- Target Recruit Count
- 30
- Registration Number
- NCT03930264
- Locations
- 🇬🇧
Nova Laboratories Limited, Leicester, Leicestershire, United Kingdom
🇬🇧Medicines Evaluation Unit Ltd Southmoor Road, Manchester, United Kingdom
Pharmacokinetics of Oral Hydroxyurea Solution
- Conditions
- Sickle Cell DiseaseSickle Cell-beta-thalassemiaSickle Cell Hemoglobin CSickle-Cell; Hemoglobin Disease, Thalassemia
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Nova Laboratories Limited
- Target Recruit Count
- 33
- Registration Number
- NCT03763656
- Locations
- 🇯🇲
Dr Angela E Rankine- Mullings, Kingston, Jamaica
🇬🇧Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom
Oral Liquid 13-cis-retinoic Acid (13-CRA)
- Conditions
- Neuroblastoma
- Interventions
- Drug: Liquid 13-Cis Retinoic AcidDrug: Extracted capsules 13-CRA
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Nova Laboratories Limited
- Target Recruit Count
- 20
- Registration Number
- NCT03291080
- Locations
- 🇬🇧
Bruce Morland, Birmingham, United Kingdom
🇬🇧Dr Antony Ng, Bristol, United Kingdom
🇬🇧Dr Amos Burke, Cambridge, United Kingdom
Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Nova Laboratories Limited
- Target Recruit Count
- 70
- Registration Number
- NCT01697020
- Locations
- 🇿🇦
Parexel International, Bloemfontein Early Phase Clinical Unit, Bloemfontein, South Africa